Clinical

Dataset Information

0

A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy


ABSTRACT: This is a single center, open-labeled, single arm phase II study aimed to investigate the efficacy and safety of fruquintinib combined with capecitabine as first-line treatment for advanced metastatic colorectal cancer patients unsuitable for intravenous chemotherapy.

DISEASE(S): Unresectable Metastatic Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2375937 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2010-08-31 | E-GEOD-21231 | biostudies-arrayexpress
2010-08-31 | GSE21231 | GEO
2023-06-19 | GSE218270 | GEO
| 2740471 | ecrin-mdr-crc
| 2365787 | ecrin-mdr-crc
2024-02-12 | GSE208114 | GEO
| 2323156 | ecrin-mdr-crc
| 2737102 | ecrin-mdr-crc
2018-09-01 | GSE108168 | GEO
2022-01-09 | ST002063 | MetabolomicsWorkbench